Exhibit 10.25

 

[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT
WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

AMENDMENT NO. 1

TO

COLLABORATION AND LICENSE AGREEMENT

 

This Amendment No. 1 (this “Amendment”), to the Collaboration
and License Agreement (the “Agreement”) dated April 5, 2016, by and between
Janssen Biotech, Inc., a Pennsylvania corporation
(“Company”), and TESARO, Inc., a Delaware corporation (“TESARO”), is entered
into as of October
10, 2016 (the “Amendment Effective Date”). Company and TESARO are sometimes referred to herein individually as a “Party” and together as the “Parties.” Capitalized terms used in this Amendment without definition have the meanings given those terms in the Agreement.

 

WHEREAS, Company is currently conducting the run-in phase (as defined in the
Development Plan) of the [***] in accordance with the Agreement;

 

WHEREAS, the Parties desire to amend the Agreement to clarify the definition of
“[***]” as currently set forth in Section 8.2(a) of the Agreement, and

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, Company
and TESARO hereby agree as follows:

 

1.        Amendments to the Agreement.    Company and TESARO agree that, as
of the Amendment Effective Date, Section 8.2(a) is hereby deleted and replaced
with the following:

 

(a)

Development Milestones.    The following payments (each, a “Development
Milestone Payment”) shall be made on a one-time basis with respect to the first
Product to achieve the corresponding milestone event (each, a “Development
Milestone”): 

 

 

Development Milestone

Development Milestone Payment (USD)

1.    [***]

$[***]

2.    [***]

$[***]

3.    [***]

$[***]

4.    [***]

$[***]

 

*  [***].  Additionally, each Development Milestone Payment may be earned upon
the achievement of an alternative Development Milestone in accordance with
Section 4.3(b).

2.        Counterparts.  This Amendment will be binding when any one or more
counterparts of it, individually or taken together, bear the signatures of each of the Parties
hereto. This Amendment No. 1 may be executed in any number of counterparts,
each of which is deemed
to be an original as against either party whose signature appears thereon, but all of which taken together constitute one and the same instrument. A facsimile or a portable document format (PDF) copy of this Amendment
No. 1, including the signature pages, will be deemed to be an original. 

 

 

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the Parties have executed this Amendment No. 1 as of the
Amendment Effective Date.

Janssen Biotech, Inc.

    

 

    

TESARO, Inc.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Victoria Vakiener

 

 

 

By:

Leon O. Moulder, Jr.

 

 

 

 

 

Name:

Victoria Vakiener

 

 

 

Name:

Leon O. Moulder, Jr.

 

 

 

 

 

Title:

VP Oncology Marketing

 

 

 

Title:

CEO

 

 

2

[***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT
WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

--------------------------------------------------------------------------------